306 related articles for article (PubMed ID: 26857699)
21. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson KD; Lunt M; Hyrich KL; ; Silman AJ; Symmons DP;
Arthritis Rheum; 2007 Sep; 56(9):2905-12. PubMed ID: 17763428
[TBL] [Abstract][Full Text] [Related]
22. Disease activity in rheumatoid arthritis and the risk of cardiovascular events.
Solomon DH; Reed GW; Kremer JM; Curtis JR; Farkouh ME; Harrold LR; Hochberg MC; Tsao P; Greenberg JD
Arthritis Rheumatol; 2015 Jun; 67(6):1449-55. PubMed ID: 25776112
[TBL] [Abstract][Full Text] [Related]
23. Has the severity of rheumatoid arthritis at presentation diminished over time?
Diffin JG; Lunt M; Marshall T; Chipping JR; Symmons DP; Verstappen SM
J Rheumatol; 2014 Aug; 41(8):1590-9. PubMed ID: 24986850
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J
Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823
[TBL] [Abstract][Full Text] [Related]
25. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis.
Crowson CS; Rollefstad S; Ikdahl E; Kitas GD; van Riel PLCM; Gabriel SE; Matteson EL; Kvien TK; Douglas K; Sandoo A; Arts E; Wållberg-Jonsson S; Innala L; Karpouzas G; Dessein PH; Tsang L; El-Gabalawy H; Hitchon C; Ramos VP; Yáñez IC; Sfikakis PP; Zampeli E; Gonzalez-Gay MA; Corrales A; Laar MV; Vonkeman HE; Meek I; Semb AG;
Ann Rheum Dis; 2018 Jan; 77(1):48-54. PubMed ID: 28877868
[TBL] [Abstract][Full Text] [Related]
26. Time-averaged DAS28 and HAQ predict cardiovascular disease in patients with rheumatoid arthritis: Data from KORONA registry.
Min HK; Kim HR; Lee SH; Kang KY; Park SH; Kwok SK
Joint Bone Spine; 2022 Oct; 89(5):105401. PubMed ID: 35513231
[TBL] [Abstract][Full Text] [Related]
27. Mortality following new-onset Rheumatoid Arthritis: has modern Rheumatology had an impact?
Holmqvist M; Ljung L; Askling J
Ann Rheum Dis; 2018 Jan; 77(1):85-91. PubMed ID: 28970218
[TBL] [Abstract][Full Text] [Related]
28. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
Kavanaugh A; Lee SJ; Curtis JR; Greenberg JD; Kremer JM; Soto L; Etzel CJ; Cox V; Yoshida K; Reed GW; Solomon DH
Ann Rheum Dis; 2015 Jun; 74(6):1150-5. PubMed ID: 25471471
[TBL] [Abstract][Full Text] [Related]
29. Impact of Treatment With Biologic Agents on the Use of Mechanical Devices Among Rheumatoid Arthritis Patients in a Large US Patient Registry.
Strand V; Greenberg JD; Griffith J; Bao Y; Saunders KC; Garg V; Li G; Ganguli A
Arthritis Care Res (Hoboken); 2016 Jul; 68(7):914-21. PubMed ID: 26555655
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register.
Chatzidionysiou K; Kristensen LE; Eriksson J; Askling J; van Vollenhoven R;
Scand J Rheumatol; 2015; 44(6):431-7. PubMed ID: 26084325
[TBL] [Abstract][Full Text] [Related]
31. No increased cardiovascular mortality among early rheumatoid arthritis patients: a nationwide register study in 2000-2008.
Kerola AM; Nieminen TV; Virta LJ; Kautiainen H; Kerola T; Pohjolainen T; Kauppi MJ; Puolakka K
Clin Exp Rheumatol; 2015; 33(3):391-8. PubMed ID: 25936374
[TBL] [Abstract][Full Text] [Related]
32. The comparison of trial data-based and registry data-based cost-effectiveness of infliximab treatment for rheumatoid arthritis in Sweden using a modeling approach.
Lekander I; Kobelt G; Svarvar P; Ljung T; van Vollenhoven R; Borgström F
Value Health; 2013; 16(2):251-8. PubMed ID: 23538176
[TBL] [Abstract][Full Text] [Related]
33. Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registries.
Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; McCroskery P; Baumgartner SW; Markenson JA
J Rheumatol; 2011 Jan; 38(1):21-8. PubMed ID: 20952478
[TBL] [Abstract][Full Text] [Related]
34. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.
Solomon DH; Avorn J; Katz JN; Weinblatt ME; Setoguchi S; Levin R; Schneeweiss S
Arthritis Rheum; 2006 Dec; 54(12):3790-8. PubMed ID: 17136752
[TBL] [Abstract][Full Text] [Related]
35. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry.
Harrold LR; Reed GW; Magner R; Shewade A; John A; Greenberg JD; Kremer JM
Arthritis Res Ther; 2015 Sep; 17(1):256. PubMed ID: 26382589
[TBL] [Abstract][Full Text] [Related]
36. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study.
Turesson C; Jarenros A; Jacobsson L
Ann Rheum Dis; 2004 Aug; 63(8):952-5. PubMed ID: 15051620
[TBL] [Abstract][Full Text] [Related]
37. Incidence of rheumatoid arthritis in Sweden: a nationwide population-based assessment of incidence, its determinants, and treatment penetration.
Eriksson JK; Neovius M; Ernestam S; Lindblad S; Simard JF; Askling J
Arthritis Care Res (Hoboken); 2013 Jun; 65(6):870-8. PubMed ID: 23281173
[TBL] [Abstract][Full Text] [Related]
38. Aspects of early arthritis. What determines the evolution of early undifferentiated arthritis and rheumatoid arthritis? An update from the Norfolk Arthritis Register.
Symmons DP; Silman AJ
Arthritis Res Ther; 2006; 8(4):214. PubMed ID: 16817941
[TBL] [Abstract][Full Text] [Related]
39. Incidence and Prevalence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis.
Lauper K; Courvoisier DS; Chevallier P; Finckh A; Gabay C
Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1756-1763. PubMed ID: 29609199
[TBL] [Abstract][Full Text] [Related]
40. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
